RBC Capital Sticks to Their Buy Rating for Design Therapeutics (DSGN)Tip Ranks·9 hours agoDSGN+280.00%
Design Therapeutics (NASDAQ:DSGN) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPSMarket Beat·2 days ago, 07:26 AMDSGN+280.00%BAC+56.00%
Design Therapeutics Q2 FY26 net loss widens to $20.2 million; R&D expenses rise to $16.4 millionPUBT·2 days ago, 07:06 AMDSGN+280.00%
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial ResultsUnusual Whales·2 days ago, 07:03 AMDSGN+280.00%
Design Therapeutics begins Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1 patientsPUBT·Jun 30 at 07:04 AMDSGN+280.00%
Pre-market hot trades in US stocks: Clinical data causes fluctuations, Design Therapeutics pre-market down 5.79%, where is market sentiment heading?Price Alert·May 19 at 07:52 AMDSGN+280.00%
U.S. stock night trading volatility: Design Therapeutics fell 3.46% in after-hours trading, as positive news failed to counteract market sentiment fluctuationsPrice Alert·May 18 at 11:01 PMDSGN+280.00%
Design Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20, Implies 39% UpsideTradingView·May 18 at 02:20 PMDSGN+280.00%PBE+17.00%
This Biotech Leader Ran Up As Much As 18% — And Then Lost It AllUnusual Whales·May 18 at 11:02 AMDSGN+280.00%XBI+74.00%
